New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Slides:

Advertisements

Similar presentations

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.

Advertisements

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

Medical Therapy for Peripheral Artery Disease

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

Emergency Management of NOAC Bleeding

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

Introduction Antiplatelet Agents ADP Receptor Antagonists.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Up to Date on Which NOAC for Which Patient

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Selecting NOACs for High-Risk Patients

Tailoring Antiplatelet Therapy in PCI

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

The Essentials for Secondary Stroke Prevention

Current State of Equipoise: The New Era of Novel Oral Anticoagulants

Treatment Options to Consider

NOACS: Emerging data in ACS/IHD

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

CV Risk Doesn't End in the Cath Lab

Identifying High-Risk AF Patients

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

Cancer-Associated Thrombosis

CAD and HF Often Coexist

A Case Challenge.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in PAD

Latest Perspectives in PAD: How to Improve Outcomes

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

Antithrombotics in Arterial Disease: Focus on Coronary Disease

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Improving Adherence to Antiplatelet Therapy After an ACS Event

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

ESC Guideline on the Management of STEMI Recommendation for DAPT

PCSK9 Inhibitors and Real-World Evidence

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics

Program Agenda

PAD: Epidemiology and Burden

CAD and PAD: Overlapping Conditions

AHA/ACC Guidelines: Antiplatelet Agents

AHA/ACC Guidelines: Oral Anticoagulation

ESC Guidelines: Antiplatelet Agents

Aspirin in PAD

CAPRIE: Clopidogrel vs Aspirin

CHARISMA: Clopidogrel Plus Aspirin vs Aspirin Alone

CHARISMA: Patients With PAD

CHARISMA: Safety Results

PEGASUS-TIMI 54: MACE in Patients With PAD

PEGASUS-TIMI 54: Bleeding Events

EUCLID: Primary Efficacy Endpoint

Antiplatelet Therapy Challenges in PAD

WAVE: Oral Anticoagulation for PAD

ATLAS ACS 2—TIMI 51: Results

COMPASS: Trial Design

Combination of Factor Xa Inhibition and Antiplatelet Therapy

COMPASS MIND

VOYAGER PAD: Study Design

VOYAGER PAD: Study Design (cont)

Edoxaban: ePAD-Study

Conclusions

Conclusions (cont)